# HeartSciences Inc.: overview HSCS · Nasdaq · CIK 1468492 · [Financials](/sectors/financials.md) · fiscal year ends Apr 30 Pages: [Overview](/companies/hscs.md) · [Financials](/companies/hscs/financials.md) · [Filings](/companies/hscs/filings.md) · [Insiders](/companies/hscs/insiders.md) Latest reported revenue: [$2.1k](/filings/0001437749-26-030319.md) for Q1 FY2027, three months to 2026-07-31, from the 10-Q filed Sep 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-030319). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [0.0](/filings/0001437749-26-008399.md) | [4.4 d](/filings/0001437749-26-024337.md) | [1.9](/filings/0001437749-26-030319.md) | [2.4](/filings/0001193125-25-319203.md) | [0.0](/filings/0001437749-26-008399.md) | [0.0 d](/filings/0001437749-26-024337.md) | [2.1](/filings/0001437749-26-030319.md) | | Gross margin | % | not reported | not reported | [56.8% d](/filings/0001437749-26-024337.md) | [60.0%](/filings/0001437749-26-030319.md) | [58.3%](/filings/0001193125-25-319203.md) | not reported | not reported | [63.8%](/filings/0001437749-26-030319.md) | | Operating margin | % | not reported | not reported | [(44147.1%) d](/filings/0001437749-26-024337.md) | [(98637.8%)](/filings/0001437749-26-030319.md) | [(85713.2%)](/filings/0001193125-25-319203.md) | not reported | not reported | [(139956.7%)](/filings/0001437749-26-030319.md) | | Net margin | % | not reported | not reported | [(48145.5%) d](/filings/0001437749-26-024337.md) | [(108157.6%)](/filings/0001437749-26-030319.md) | [(97179.4%)](/filings/0001193125-25-319203.md) | not reported | not reported | [(151064.0%)](/filings/0001437749-26-030319.md) | | Diluted EPS | $ per share | [(2.27)](/filings/0001193125-25-319203.md) | [(2.57)](/filings/0000950170-25-038699.md) | not reported | [(1.58)](/filings/0001468492-25-000010.md) | [(0.85)](/filings/0001193125-25-319203.md) | not reported | not reported | not reported | | Free cash flow | $k | not reported | [(1,620) d](/filings/0001437749-26-008399.md) | [(1,591) d](/filings/0001437749-26-024337.md) | not reported | not reported | [(1,472) d](/filings/0001437749-26-008399.md) | [(1,677) d](/filings/0001437749-26-024337.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-04-30) | FY2023 (2023-04-30) | FY2024 (2024-04-30) | FY2025 (2025-04-30) | FY2026 (2026-04-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [14.4](/filings/0000950170-23-033424.md) | [5.2](/filings/0000950170-24-087271.md) | [18.6](/filings/0000950170-25-098326.md) | [4.4](/filings/0001437749-26-024337.md) | [4.3](/filings/0001437749-26-024337.md) | | Gross margin | % | [45.1%](/filings/0000950170-23-033424.md) | [45.7%](/filings/0000950170-24-087271.md) | [67.3%](/filings/0000950170-25-098326.md) | [56.8%](/filings/0001437749-26-024337.md) | [59.1%](/filings/0001437749-26-024337.md) | | Operating margin | % | [(32765.6%)](/filings/0000950170-23-033424.md) | [(118698.3%)](/filings/0000950170-24-087271.md) | [(33902.0%)](/filings/0000950170-25-098326.md) | [(192013.1%)](/filings/0001437749-26-024337.md) | [(194787.4%)](/filings/0001437749-26-024337.md) | | Net margin | % | [(33592.6%)](/filings/0000950170-23-033424.md) | [(123384.3%)](/filings/0000950170-24-087271.md) | [(35511.9%)](/filings/0000950170-25-098326.md) | [(201499.5%)](/filings/0001437749-26-024337.md) | [(211666.5%)](/filings/0001437749-26-024337.md) | | Diluted EPS | $ per share | [(1.45)](/filings/0000950170-23-033424.md) | [(80.00)](/filings/0000950170-24-087271.md) | [(18.74)](/filings/0000950170-25-098326.md) | [(9.34)](/filings/0000950170-25-098326.md) | not reported | | Free cash flow | $k | [(3,646)](/filings/0000950170-23-033424.md) | [(5,792)](/filings/0000950170-24-087271.md) | [(6,135)](/filings/0000950170-25-098326.md) | [(7,416)](/filings/0001437749-26-024337.md) | [(7,430)](/filings/0001437749-26-024337.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hscs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TFB Advisors LLC](/funds/1965201.md) | 2026-06-30 | $74.6k | 29,740 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $57.9k | 23,049 | | Reduced −5,889 | | [Astoria Strategic Wealth, Inc.](/funds/1777914.md) | 2026-06-30 | $47.5k | 18,927 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $45.1k | 17,968 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $43.3k | 17,239 | | Unchanged | | [Tradition Wealth Management, LLC](/funds/1843010.md) | 2026-06-30 | $42.2k | 16,819 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $36.4k | 14,488 | | New +14,488 | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $14.7k | 5,859 | | New +5,859 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $14.6k | 5,812 | | Reduced −664 | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $13.6k | 270,770 | | Unchanged | ## Recent filings [All 342 filings](/companies/hscs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 21:30 ET | [SCHEDULE 13D/A](/filings/0001213900-26-112224.md) | Ownership report, active investor, amended | 0001213900-26-112224 | | 2026-10-06 | 16:30 ET | [8-K](/filings/0001213900-26-107238.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-107238 | | 2026-10-02 | 17:15 ET | [8-K](/filings/0001213900-26-106500.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001213900-26-106500 | | 2026-09-17 | 08:01 ET | [8-K](/filings/0001213900-26-100752.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-100752 | | 2026-09-15 | 17:02 ET | [8-K](/filings/0001213900-26-100185.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-100185 | | 2026-09-14 | 16:14 ET | [10-Q](/filings/0001437749-26-030319.md) | Quarterly report, period 2026-07-31 | 0001437749-26-030319 | | 2026-08-20 | 07:43 ET | [8-K](/filings/0001213900-26-091893.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-091893 | | 2026-08-19 | 17:11 ET | [8-K/A](/filings/0001213900-26-091764.md) | 9.01 Financial statements and exhibits | 0001213900-26-091764 | | 2026-08-19 | 16:45 ET | [8-K](/filings/0001213900-26-091720.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-091720 | | 2026-08-18 | 20:13 ET | [SCHEDULE 13D](/filings/0001213900-26-091367.md) | Ownership report, active investor | 0001213900-26-091367 | ## Latest annual report [Form 10-K for the fiscal year ended Apr 30, 2026](/filings/0001437749-26-024337.md), filed Jul 23, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1468492 - Tickers: HSCS, HSCSW - Exchange: Nasdaq - SIC code: 6199 Finance Services - State of incorporation: TX - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:27 ET. No prices; not investment advice.